Discovery Platform

Taurus Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Ligand Expands Omniab® Antibody Discovery Platform Through the Acquisitions of Taurus Biosciences

Lead Product(s): Mono- and Bispecific human antibodies

Therapeutic Area: Oncology Product Name: OmniAb

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

Deal Size: $5.0 million Upfront Cash: $5.0 million

Deal Type: Acquisition September 14, 2020

Details:

The acquisitions are expected to enable Ligand to secure new license agreements with expanded economics as a result of the addition of tools and intellectual property that Ligand can now offer to partners.

Xcella Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Ligand Expands Omni AB® Antibody Discovery Platform Through the Acquisitions of X Cella Biosciencesandd Taurus Biosciences

Lead Product(s): Mono- and Bispecific human antibodies

Therapeutic Area: Oncology Product Name: OmniAb

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

Deal Size: $7.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition September 10, 2020

Details:

The acquisition will strengthen company's OmniAb® technology platform. Potential for two approvals of OmniAb-derived antibodies in 2021 with expected new royalty streams to Ligand.

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Huadong Medicine and Exscientia Enter Co-Development Partnership to Accelerate Oncology Drug Discovery Through Artificial Intelligence

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Small molecule

Partner/Sponsor/Collaborator: Exscientia

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership September 09, 2020

Details:

Under this collaboration, Exscientia will use its advanced Centaur Chemist AI platform to design new molecules against project specific targets and Huadong will apply its experimental and managerial capabilities to support Exscientia’s AI design in a rapid closed-loop cycle.

Horizon Discovery Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics

Lead Product(s): Chinese Hamster Ovary K1 cell

Therapeutic Area: Oncology Product Name: Chosource

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: TrueBinding

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 29, 2020

Details:

TrueBinding will use Horizon’s cGMP-compliant CHOSOURCE™ platform for the development and commercialization of multiple biotherapeutic products for applications in immuno-oncology and other disease areas with great unmet medical need.

Omega Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Omega Therapeutics Advances Controllable Epigenomic Programming Platform to Deliver a Pipeline of Novel Therapeutics with $85M in Financing

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $85.0 million Upfront Cash: Undisclosed

Deal Type: Financing July 29, 2020

Details:

Financing proceeds support identification of novel therapeutic targets and enable genomic medicine programs across a wide range of therapeutic areas

Syracuse Biopharma

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China

Lead Product(s): T-cell therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: JW Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition July 20, 2020

Details:

JW Therapeutics has acquired Syracuse Biopharma, which includes the license for Eureka Therapeutics’ ARTEMIS® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.

Alteogen, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Alteogen Enters into a Global License Agreement with a Top Ten Pharma

Lead Product(s): ALT-B4

Therapeutic Area: Oncology Product Name: ALT-B4

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $3,881.0 million‬ Upfront Cash: $16.0 million

Deal Type: Licensing Agreement June 24, 2020

Details:

Under the terms of the agreement, Alteogen has granted worldwide rights for TTPC to develop multiple products in combination with ALT-B4.

panCELLa

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

panCELLa Receives Research and Development Support for Cell Therapy

Lead Product(s): Human embryonic stem cells

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: NRC IRAP

Deal Size: $0.4 million Upfront Cash: Undisclosed

Deal Type: Funding April 07, 2020

Details:

Support from NRC IRAP will go toward the research and development of a two-step safety switch known as panKiller.

Ultragenyx Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology

Lead Product(s): AAV-based gene therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd

Deal Size: $225.0 million Upfront Cash: $125.0 million

Deal Type: Licensing Agreement April 01, 2020

Details:

Ultragenyx granted Daiichi Sankyo license to intellectual property, including know-how and patent applications, with respect to its HeLa manufacturing platform for AAV-based gene therapy products.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Taurus Biosciences

Ligand Expands Omniab® Antibody Discovery Platform Through the Acquisitions of Taurus Biosciences

Xcella Biosciences

Ligand Expands Omni AB® Antibody Discovery Platform Through the Acquisitions of X Cella Biosciencesandd Taurus Biosciences

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd

Huadong Medicine and Exscientia Enter Co-Development Partnership to Accelerate Oncology Drug Discovery Through Artificial Intelligence

Horizon Discovery Group

Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics

Omega Therapeutics

Omega Therapeutics Advances Controllable Epigenomic Programming Platform to Deliver a Pipeline of Novel Therapeutics with $85M in Financing

Syracuse Biopharma

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China

Alteogen, Inc

Alteogen Enters into a Global License Agreement with a Top Ten Pharma

panCELLa

panCELLa Receives Research and Development Support for Cell Therapy

Ultragenyx Pharmaceutical

Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology